The FDA has added a new indication to the oral JAK inhibitor Cibinqo (abrocitinib) - now approved to treat atopic dermat

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
The FDA has added a new indication to the oral JAK inhibitor Cibinqo (abrocitinib) - now approved to treat atopic dermatitis in adolescents 12 to under 18 years old. (Approval is based on a phase 3 JADE TEEN trial. https://t.co/DsQj3BfPmZ https://t.co/0bpb2FAwpg
Links
https://bit.ly/3Ym4FhT

An open-label trial of 170 adults w/ IgA Nephropathy (proteinuria >1 g/d) evaluated addition of mycophenolate to stan

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
An open-label trial of 170 adults w/ IgA Nephropathy (proteinuria >1 g/d) evaluated addition of mycophenolate to standard care (SC). MMF (1.5g/d) associated w/ less renal worsening - 7.1% MMF + SC vs. 21% SC alone (aHR 0.23; 95% CI, 0.09-0.63) https://t.co/FlcafoZi3U https://t.co/tQkZE8RRyy
Links
https://bit.ly/3jHEvXB

Meta-analysis (21 studies, 3948 pregnant pts) HCQ may reduce risk of preeclampsia (OR 0.45) & premature delivery (O

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Meta-analysis (21 studies, 3948 pregnant pts) HCQ may reduce risk of preeclampsia (OR 0.45) & premature delivery (OR 0.84) in pregnant autoimmune pts. HCQ may also reduce risk of gestational HTN (OR 0.42) & pre-term birth (OR 0.63) in pregnant SLE pts https://t.co/riQDRN9r1A https://t.co/uR8Nem4Ndx
Links
https://bit.ly/3XmVJHA

Benlysta granted Orphan Drug Designation by US FDA as potential Rx of systemic sclerosis, such status facilitates eval i

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Benlysta granted Orphan Drug Designation by US FDA as potential Rx of systemic sclerosis, such status facilitates eval in rare diseases. GSK is planning a trial of belimumab for SSc-associated interstitial lung disease in the first half of 2023 https://t.co/kWItB7NEvn https://t.co/eVbQtKy98H
Links
https://bit.ly/3Xj2YjZ

KNOW YOUR NUMBERS! (2.10.2023)

10 February 2023
KNOW YOUR NUMBERS! (2.10.2023)

Dr. Jack Cush reviews the news, journal articles and the numbers, from the past week on RheumNow.com.

  1. Enthesitis-related arthritis compared in kids - 105 ERA (57 axial vs 48 peripheral). Axial ERA pts were older @onset (12 vs. 11yrs), longer Dx delay(10 vs. 5 mos), higher inflammatory markers, more Hip Dz (53% vs 27%), more biologic Rx (67% vs 21%) https://bit.ly/3DSNMmL

Enthesitis-related arthritis compared in kids - 105 ERA (57 axial vs 48 peripheral). Axial ERA pts were older @onset (1

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Enthesitis-related arthritis compared in kids - 105 ERA (57 axial vs 48 peripheral). Axial ERA pts were older @onset (12 vs. 11yrs), longer Dx delay(10 vs. 5 mos), higher inflammatory markers, more Hip Dz (53% vs 27%), more biologic Rx (67% vs 21%) https://t.co/KTYn1kv3qO https://t.co/eWbvMSBLxm
Links
https://bit.ly/3DSNMmL

211 Adult Crohn's pts w/ steroid-free remission >6mo on Combo infliximab & immunosuppressant either cont combo or

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
211 Adult Crohn's pts w/ steroid-free remission >6mo on Combo infliximab & immunosuppressant either cont combo or W/D IFX or Immsup. 2-yr relapse rates: 14% Combo vs, 36% IFX vs 10% Immunosup. WD of IFX had 3.45-4.76 fold incr rsk of flare https://t.co/6EbM3Vx0Ei https://t.co/5ZOE2oxCl0
Links
https://bit.ly/3DT9mqW

Did you have a chance to listen to last week's RheumNow podcast? Dr. Cush covers rheumatology news from the last week.

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Did you have a chance to listen to last week's RheumNow podcast? Dr. Cush covers rheumatology news from the last week. Make sure to tune in before we release our next episode tomorrow! https://t.co/uRRg2K2K1a https://t.co/MjWF3Zl05i
Links
https://bit.ly/3lnABUu
9 February 2023
Without DMARDS, Shoulder Arthroplasty Increasing in Rheumatoid Arthritis

The need for total shoulder arthroplasty (TSA) in rheumatoid arthritis (RA) patients appears to depend on the use of disease modifying antirheumatic drugs (DMARDs), according to Seminars in Arthroplasty.

Subscribe to
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×